GI Oncologist
Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.
Amal Therapeutics, Aptitude Health, Amgen, Astellas, Astra Zeneca, Beigene, BMS, Celgene, Daiichi Sankyo, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Novartis, Pfizer, Roche, Sai-Med, Servier, Viracta, Zymeworks
Practice-changing upper GI trial data direct from ASCO 2024
GI oncologists review the latest data presented at ASCO 2024
Episode 1: Non-metastatic cancer patient case
Episode 2: Metastatic cancer patient case
Video recording
Episode 2: Non-metastatic Gastroesophageal Cancers